Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03205358
Other study ID # MET54
Secondary ID 2014-004367-20U1
Status Completed
Phase Phase 2
First received
Last updated
Start date March 31, 2015
Est. completion date August 19, 2015

Study information

Verified date March 2022
Source Sanofi
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of the study was to evaluate the immunogenicity and safety profile of a single dose of Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid (MenACYW) Conjugate vaccine when given alone compared to that of the licensed Meningococcal groups A, C, W 135 and Y (NIMENRIX®) Conjugate vaccine. Observational objectives: - To evaluate the antibody responses to the antigens (serogroups A, C, Y, and W) present in MenACYW Conjugate vaccine and NIMENRIX® measured by serum bactericidal assay using baby rabbit complement (rSBA) and by serum bactericidal assay using human complement (hSBA) - To evaluate the antibody responses against tetanus in participants who received MenACYW Conjugate vaccine or NIMENRIX® vaccine - To evaluate the safety profile of MenACYW Conjugate vaccine and NIMENRIX®


Description:

All participants received 1 dose of MenACYW Conjugate vaccine or NIMENRIX® on Day 0 and were evaluated for immunogenicity and safety profile. The duration of each participant's participation in the trial was 30 to 44 days.


Recruitment information / eligibility

Status Completed
Enrollment 188
Est. completion date August 19, 2015
Est. primary completion date August 19, 2015
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 12 Months to 23 Months
Eligibility Inclusion Criteria: - Aged 12 to 23 months on the day of the first study visit. - Born at full term of pregnancy (greater than or equal to [=] 37 weeks) or with a birth weight =2.5 kilogram (kg) (5.5 pounds). - Inform Consent Form (ICF) had been signed and dated by the parent(s) or other legally acceptable representative (and by an independent witness if required by local regulations). - Participant and parent/legally acceptable representative were able to attend all scheduled visits and to comply with all trial procedures. - Covered by health insurance where applicable. Exclusion Criteria: - Participation at the time of study enrollment (or in the 4 weeks preceding the trial vaccination) or planned participation during the present trial period in another clinical trial investigating a vaccine, drug, medical device, or medical procedure. - Receipt of any vaccine in the 4 weeks preceding the trial vaccination or planned receipt of any vaccine before the final blood draw except for influenza vaccination, which might be received at least 2 weeks before or after the study vaccine. - Previous vaccination against meningococcal disease with either the trial vaccine or mono-, or polyvalent polysaccharide or Conjugate meningococcal vaccine containing serogroups A, B, C, W, or Y. - Receipt of immune globulins, blood, or blood-derived products in the past 3 months. - Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy, within the preceding 6 months; or long-term systemic corticosteroid therapy (= 2 milligram [mg]/kg/day of prednisone or equivalent for more than 2 consecutive weeks within the past 3 months). - History of meningococcal infection, confirmed either clinically, serologically, or microbiologically. - At high risk for meningococcal infection during the trial (i.e., participants with persistent complement deficiency, with anatomic or functional asplenia, or participants travelling to countries with high endemic or epidemic disease). - Known systemic hypersensitivity to any of the vaccine components, or history of a life-threatening reaction to the vaccines used in the trial or to a vaccine containing any of the same substances. - Known systemic hypersensitivity to latex. - Known thrombocytopenia, as reported by the parent/legally acceptable representative. - Bleeding disorder or receipt of anticoagulants in the 3 weeks preceding inclusion, contraindicating IM vaccination. - Personal history of Guillain-Barré syndrome. - Personal history of an Arthus-like reaction after vaccination with a tetanus toxoid-containing vaccine. - Chronic illness that, in the opinion of the Investigator, was at a stage where it might interfere with trial conduct or completion. - Moderate or severe acute illness/infection (according to Investigator judgment) on the day of vaccination or febrile illness (temperature =38.0 degree Celsius (°C). A prospective participant should not be included in the study until the condition had resolved or the febrile event had subsided. - Receipt of oral or injectable antibiotic therapy within 72 hours prior to the first blood draw. - Identified as a natural or adopted child of the Investigator or employee with direct involvement in the proposed study.

Study Design


Intervention

Biological:
Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine
0.5 milliliter (mL), Intramuscular (IM)
Meningococcal Polysaccharide groups A, C, W-135 and Y Conjugate Vaccine
0.5 mL, IM

Locations

Country Name City State
Finland Investigational Site Number 005 Espoo
Finland Investigational Site Number 002 Helsinki
Finland Investigational Site Number 006 Helsinki
Finland Investigational Site Number 007 Järvenpää
Finland Investigational Site Number 008 Oulu
Finland Investigational Site Number 001 Pori
Finland Investigational Site Number 003 Tampere
Finland Investigational Site Number 004 Turku

Sponsors (1)

Lead Sponsor Collaborator
Sanofi Pasteur, a Sanofi Company

Country where clinical trial is conducted

Finland, 

References & Publications (1)

Vesikari T, Borrow R, Forsten A, Findlow H, Dhingra MS, Jordanov E. Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in healthy toddlers: a Phase II randomized study. Hum Vaccin Immunother. 2020 Jun 2 — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Participants Reporting Solicited Injection-Site and Systemic Reaction Following Vaccination With Either MenACYW Conjugate Vaccine or NIMENRIX® A solicited reaction was defined as an adverse reaction (AR) observed and reported under the conditions (symptom and onset) prelisted (i.e., solicited) in the case report form (CRF) and considered as related to vaccination. Solicited injection site reactions: Tenderness, Erythema, and Swelling. Solicited systemic reactions: Fever, Vomiting, Crying abnormal, Drowsiness, Appetite lost, and Irritability. Grade 3 solicited injection site reactions: Tenderness: cries when injected limb was moved or the movement of the injected limb was reduced; Erythema and Swelling: greater than or equal to (=) 50 millimeter (mm). Grade 3 solicited systemic reactions: Fever: greater than [>] 39.5 degree Celsius (°C); Vomiting: =6 episodes per 24 hours or requiring parenteral hydration; crying abnormal: >3 hours; Drowsiness: sleeping most of the time or difficult to wake up; Appetite lost: refuses =3 feeds or refuses most feeds; Irritability: inconsolable. Day 0 up to Day 7 post-vaccination
See also
  Status Clinical Trial Phase
Withdrawn NCT03445416 - Increasing Healthcare Engagement Via Routine Vaccination Among Young Black Men Who Have Sex With Men N/A
Completed NCT02526394 - Pertussis and Meningitis C Concomitant Vaccination in Adolescents Phase 4
Completed NCT01442675 - Study of a Single Dose of Menactra® Vaccine 4-6 Years After Prior Menactra Vaccine Phase 2
Completed NCT00539032 - Immunology and Safety of Menactra® in Children in Saudi Arabia Phase 3
Terminated NCT00428051 - Colombia Epidemiologic Surveillance Study N/A
Recruiting NCT05496673 - Meningitis: Burden, Causes, Screening and Prevention in Rural Northern Uganda N/A
Completed NCT02003495 - Immunogenicity and Safety of Meningococcal (A, C, Y and W135) Conjugate Vaccine Phase 3
Recruiting NCT00901602 - Lebanese Interhospital Pneumococcal Surveillance Program
Completed NCT00850603 - Safety and Immunogenicity of Intradermal Versus Subcutaneous Doses of Menomune® Phase 4
Completed NCT02591290 - Immunogenicity and Safety of Two-Dose Series of Menactra® in Japanese Healthy Adult Subjects Phase 4
Completed NCT03112031 - Treatment With Tamoxifen in Cryptococcal Meningitis Phase 2
Completed NCT02881957 - Hypovitaminosis D in Neurocritical Patients Phase 2/Phase 3
Completed NCT06334796 - Artificial Intelligence-powered Virtual Assistant for Emergency Triage in Neurology Early Phase 1
Completed NCT03378258 - Petechiae In Children (PIC) Study: Defining A Clinical Decision Rule for The Management Of Fever and Non-Blanching Rashes In Children Including The Role Of Point Of Care Testing For Procalcitonin & Neisseria Meningitidis DNA.
Recruiting NCT05637645 - Different Approaches of Spinal Anesthesia in Patients Undergoing Cesarean Section N/A
Completed NCT02841254 - Diagnostic Performance of Clinical Signs Patients Suspected of Meningitis to Emergencies N/A
Completed NCT02003313 - Immunogenicity and Safety of Group A, C, Y and W135 Meningococcal Polysaccharide Vaccine Phase 3
Recruiting NCT01619462 - Safety and Immunogenicity of 10-valent and 13-valent Pneumococcal Conjugate Vaccines in Papua New Guinean Children Phase 3
Completed NCT01239043 - Antibody Persistence and Response to Re-vaccination With Either Menactra® or Menomune® 3 Years After Initial Vaccination Phase 2
Completed NCT00495690 - Impact of Daily Zinc Supplementation to Infants Born With Low Birth Weight on Death and Severe Disease Phase 3